A Study of IOV-5001 in Adults With Advanced Solid Tumors
← catalyst calendarNCT07743723 · readout ≤ 2,780 d
Sponsored by Iovance Biotherapeutics, Inc. (industry) · IOVA — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
106estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Aug 2026 | estimated | When the study began enrolling |
| Primary completion | Mar 2034 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2044 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumors
- Non-Small Cell Lung Cancer
- Triple Negative Breast Cancer (TNBC)
- Colorectal Cancer
- Head and Neck Squamous Cell Carcinoma
- Metastatic Solid Tumors
- Unresectable Solid Tumor
Intervention
- Biological: IOV-5001
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Safety Assessment
measured Up to 30 days
Phase 2: Efficacy Measured by Overall Response Rate (ORR)
measured Up to 5 years
Permalink · IOVA's whole pipeline · Catalyst calendar · Every registered study · What changed